CB24 Development of a natural therapeutic treatment for late-stage lung cancer patients
- Coordinator
- Celtic Biotech Ltd, Ireland
- Runs
- 1 October 2023 to 31 July 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.9m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190166095
What the project is doing
In the project's own words, from its summary on CORDIS.
Celtic Biotech Ireland has developed CB24(Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life changing treatment of Non-Small Cell Lung Cancer (NSCLC). Delivered intravenously, CB24 induces predictable and consistent apoptosis (cell death) and autophagy (degradation) in human lung carcinoma cells. CB24 outclass the competitive NSCLC treatment solutions (surgery, chemotherapy, and radiotherapy) through its efficacy, safety, minimal side-effects, easy to use home based treatment and suitability for all patients including those at stage 3 & 4.Celtic have already proven the efficacy of CB24 through pre-clinical and FIH clinical trials.
Through the proposed 24months EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Celtic Biotech Ltd | Dublin | Ireland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI